Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NARINDER SAINI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1356420665
CMS profile
1142372
Location
SPRINGFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$12.83

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $12.83 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alkermes, Inc. $12.83 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NARINDER SAINI

NPI 1356420665 · CMS profile ID 1142372

Allopathic & Osteopathic Physicians / Internal Medicine

SPRINGFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $12.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $12.8304/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686626397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12.83 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $9,450.00 1
PY2024 Principal investigator $23,855.10 5
PY2023 Recipient $11,082.59 1
PY2023 Principal investigator $9,599.85 7
PY2022 Recipient $3,897.05 1
PY2022 Principal investigator $1,244,253.27 83
PY2021 Recipient $434,945.60 1
PY2021 Principal investigator $917,788.30 69
PY2020 Recipient $15,112.10 3
PY2020 Principal investigator $408,488.40 195
PY2019 Recipient $586.07 1
PY2019 Principal investigator $552,873.53 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $30.00 12/30/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851032255
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $375.00 12/30/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851032257
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 12/21/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 860872285
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,995.00 12/17/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851031759
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,000.00 12/17/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851031765
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $400.00 12/17/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851031771
Principal investigator 1 GlaxoSmithKline, LLC. $2,100.36 12/15/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 809510289
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,995.00 11/22/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851030325
Principal investigator 1 Partner Therapeutics, Inc. $900.00 11/19/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804849
Principal investigator 1 Partner Therapeutics, Inc. $427.50 11/12/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804549
Principal investigator 1 Partner Therapeutics, Inc. $900.00 11/12/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804775
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $17,432.50 10/22/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851028785
Principal investigator 1 Partner Therapeutics, Inc. $950.00 10/22/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804687
Principal investigator 1 Partner Therapeutics, Inc. $665.00 10/22/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804827
Principal investigator 1 Partner Therapeutics, Inc. $1,330.00 10/22/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804829
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,810.00 10/20/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838910355
Recipient Celltrion, Inc. $434,945.60 10/15/2021 Covered Recipient Physician CT-P59 3.2 No dispute reported 06/30/2026 829111551
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $15,413.75 09/27/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027667
Principal investigator 1 Partner Therapeutics, Inc. $1,693.46 09/27/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804753
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,788.00 09/23/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838910115
Principal investigator 1 Partner Therapeutics, Inc. $1,173.46 09/21/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804675
Principal investigator 1 Partner Therapeutics, Inc. $850.00 09/16/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804513
Principal investigator 1 Partner Therapeutics, Inc. $2,213.46 09/09/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804673
Principal investigator 1 Vanda Pharmaceuticals Inc. $106.00 09/08/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838909971
Principal investigator 1 Partner Therapeutics, Inc. $665.00 09/03/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804371
Principal investigator 1 Partner Therapeutics, Inc. $285.00 09/03/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804685
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,530.00 08/31/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027185
Principal investigator 1 Vanda Pharmaceuticals Inc. $18,014.00 08/25/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838909789
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,000.00 08/18/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838909663
Principal investigator 1 Partner Therapeutics, Inc. $1,040.00 08/16/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804599
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,000.00 08/05/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838909557
Principal investigator 1 Partner Therapeutics, Inc. $1,693.46 07/29/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804597
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $7,000.00 07/26/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE AND RESEARCH
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026447
Principal investigator 1 GlaxoSmithKline, LLC. $52.00 07/22/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 809516160
Principal investigator 1 Vanda Pharmaceuticals Inc. $750.00 07/21/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838909415
Principal investigator 1 Vanda Pharmaceuticals Inc. $17,828.00 07/14/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838909285
Principal investigator 1 GlaxoSmithKline, LLC. $52.00 07/01/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 809492621
Principal investigator 1 Vanda Pharmaceuticals Inc. $250.00 06/23/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838909041
Principal investigator 1 Partner Therapeutics, Inc. $950.00 06/11/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804607
Principal investigator 1 Partner Therapeutics, Inc. $8,075.00 06/04/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804825
Principal investigator 1 Vanda Pharmaceuticals Inc. $12,380.00 05/19/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838908653
Principal investigator 1 Eli Lilly and Company $47.90 05/18/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 819467593
Principal investigator 1 Genentech, Inc. $311.00 05/18/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
TRANSMISSION STUDY HOUSEHOLD No dispute reported 06/30/2026 836042883
Principal investigator 1 Genentech, Inc. $4,000.00 05/04/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
TRANSMISSION STUDY HOUSEHOLD No dispute reported 06/30/2026 836042877
Principal investigator 1 Abbott Laboratories $5,000.00 04/15/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827570199
Principal investigator 1 GlaxoSmithKline, LLC. $360.00 04/09/2021 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 809524289
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,850.00 03/25/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838907935
Principal investigator 1 Allergan, Inc. $5,522.00 03/17/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789001587
Principal investigator 1 Vanda Pharmaceuticals Inc. $28,994.00 03/16/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838907855
Principal investigator 1 Vanda Pharmaceuticals Inc. $23,688.00 03/10/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838907739
Principal investigator 1 Partner Therapeutics, Inc. $3,583.46 03/09/2021 Non-covered Recipient Entity
Urgent Care Specialists, LLC
SCOPE No dispute reported 06/30/2026 809804915
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,500.00 02/24/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838907637
Principal investigator 1 Vanda Pharmaceuticals Inc. $12,050.00 02/10/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838907489
Principal investigator 1 Abbott Laboratories $48,295.00 02/08/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827570197
Principal investigator 1 Allergan, Inc. $347.00 02/05/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 789001585
Principal investigator 1 Allergan, Inc. $2,654.00 02/01/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789001583
Principal investigator 1 Allergan, Inc. $1,738.50 01/27/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789001581
Principal investigator 1 Abbott Laboratories $2,475.00 01/26/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827570193
Principal investigator 1 Abbott Laboratories $1,200.00 01/26/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827570195
Principal investigator 1 Allergan, Inc. $1,883.80 01/26/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789001577
Principal investigator 1 Allergan, Inc. $1,707.00 01/26/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 789001579
Principal investigator 1 Eli Lilly and Company $18,605.25 01/26/2021 Non-covered Recipient Entity
NORTHWEST CLINICAL RESEARCH CENTER
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819463991
Principal investigator 1 Eli Lilly and Company $10,642.94 01/26/2021 Non-covered Recipient Entity
NORTHWEST CLINICAL RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 819464419
Principal investigator 1 Allergan, Inc. $245.50 01/22/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 789001575
Principal investigator 1 Vanda Pharmaceuticals Inc. $650.00 01/21/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838907313
Principal investigator 1 Vanda Pharmaceuticals Inc. $19,278.00 01/14/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838907175
Principal investigator 1 Abbott Laboratories $15,000.00 01/11/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol No dispute reported 06/30/2026 827570191
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,350.00 01/06/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 838907071
Principal investigator 1 Eli Lilly and Company $365,679.00 01/04/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 819469275
Principal investigator 1 Eli Lilly and Company $197,018.00 01/04/2021 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819470851